Karen H Lu

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Gynecologic Cancers in Lynch Syndrome/HNPCC
    Karen H Lu
    Department of Gynecologic Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Fam Cancer 4:249-54. 2005
  2. pmc Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy
    David A Iglesias
    Corresponding Author Karen H Lu, Department of Gynecologic Oncology and Reproductive Medicine, 1155 Hermann Pressler Dr, Unit 1362, Houston, TX 77030
    Mol Cancer Ther 12:2847-56. 2013
  3. pmc Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome
    Karen H Lu
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 6:774-81. 2013
  4. pmc Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention
    Karen H Lu
    H E B Professor of Cancer Research, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Fam Cancer 12:273-7. 2013
  5. pmc FATS is a transcriptional target of p53 and associated with antitumor activity
    Xifeng Zhang
    Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
    Mol Cancer 9:244. 2010
  6. pmc Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer
    Chan H Han
    Department of Epidemiology, The University of Texas M, d, Anderson Cancer Center, Houston, TX 77030, USA
    J Exp Clin Cancer Res 30:5. 2011
  7. doi request reprint The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention
    Karen H Lu
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Cancer Prev Res (Phila) 2:773-5. 2009
  8. pmc Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations
    Robin A Lacour
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030 3721, USA
    Gynecol Oncol 121:358-63. 2011
  9. doi request reprint Management of early-stage endometrial cancer
    Karen H Lu
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 36:137-44. 2009
  10. ncbi request reprint Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis
    Karen H Lu
    Department of Gynecologic Oncology, Clinical Cancer Genetics, UT M D Anderson Cancer Center, Houston, TX 77030, USA
    Fam Cancer 7:53-8. 2008

Research Grants

Collaborators

Detail Information

Publications106 found, 100 shown here

  1. ncbi request reprint Gynecologic Cancers in Lynch Syndrome/HNPCC
    Karen H Lu
    Department of Gynecologic Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Fam Cancer 4:249-54. 2005
    ..With increasing evidence that women with Lynch/HNPCC have significant risks for both colon and endometrial cancers, we believe a multi-disciplinary approach to the management of these individuals is crucial...
  2. pmc Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy
    David A Iglesias
    Corresponding Author Karen H Lu, Department of Gynecologic Oncology and Reproductive Medicine, 1155 Hermann Pressler Dr, Unit 1362, Houston, TX 77030
    Mol Cancer Ther 12:2847-56. 2013
    ..These studies provide a rationale for clinical trials using metformin in combination with PI3K-targeted agents for tumors harboring activating K-Ras mutations, and reveal a novel mechanism of action for metformin...
  3. pmc Prospective multicenter randomized intermediate biomarker study of oral contraceptive versus depo-provera for prevention of endometrial cancer in women with Lynch syndrome
    Karen H Lu
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Prev Res (Phila) 6:774-81. 2013
    ..These results show that women with Lynch syndrome do show an endometrial response to short-term exogenous progestins, suggesting that OCP and depo-MPA may be reasonable chemopreventive agents in this high-risk patient population...
  4. pmc Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention
    Karen H Lu
    H E B Professor of Cancer Research, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Fam Cancer 12:273-7. 2013
    ....
  5. pmc FATS is a transcriptional target of p53 and associated with antitumor activity
    Xifeng Zhang
    Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
    Mol Cancer 9:244. 2010
    ..FATS expression was silent or downregulated in human cancers, and overexpression of FATS suppressed tumorigenicity in vivo independently of p53. Our results reveal FATS as a p53-regulated gene to monitor genomic stability...
  6. pmc Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer
    Chan H Han
    Department of Epidemiology, The University of Texas M, d, Anderson Cancer Center, Houston, TX 77030, USA
    J Exp Clin Cancer Res 30:5. 2011
    ..SULF1 expression has been reported to be decreased in various cancers, including ovarian cancer. We hypothesized that single nucleotide polymorphisms (SNPs) of SULF1 would impact clinicopathologic characteristics...
  7. doi request reprint The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention
    Karen H Lu
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Cancer Prev Res (Phila) 2:773-5. 2009
    ..792 in this issue of the journal) discusses the available animal models of ovarian cancer, including the laying hen, non-human primate, and transgenic rodent models, and their relevance to ovarian cancer chemoprevention studies...
  8. pmc Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations
    Robin A Lacour
    The University of Texas M D Anderson Cancer Center, Houston, TX 77030 3721, USA
    Gynecol Oncol 121:358-63. 2011
    ..We also sought to account for "survival bias" by minimizing lead time that may exist between diagnosis and genetic testing...
  9. doi request reprint Management of early-stage endometrial cancer
    Karen H Lu
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 36:137-44. 2009
    ..New molecular markers may be helpful in the future to refine our ability to identify high-risk, early-stage patients...
  10. ncbi request reprint Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis
    Karen H Lu
    Department of Gynecologic Oncology, Clinical Cancer Genetics, UT M D Anderson Cancer Center, Houston, TX 77030, USA
    Fam Cancer 7:53-8. 2008
    ..For those women without cancer who are found to have a hereditary cancer syndrome, effective counseling in the prevention and early detection of cancers is crucial...
  11. ncbi request reprint Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome
    Karen H Lu
    Department of Gynecologic Oncology, Division of Surgery, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Obstet Gynecol 105:569-74. 2005
    ..The purpose of this study was to estimate whether women with hereditary nonpolyposis colorectal cancer syndrome who develop 2 primary cancers present with gynecologic or colon cancer as their "sentinel cancer."..
  12. ncbi request reprint Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer
    Karen H Lu
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030 4009, USA
    J Clin Oncol 25:5158-64. 2007
    ..The purpose of this study was to determine the prevalence of MLH1, MSH2, and MSH6 mutations in an unselected cohort of women diagnosed with endometrial cancer at age younger than 50 years...
  13. ncbi request reprint Update on the management of ovarian germ cell tumors
    Karen H Lu
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Reprod Med 50:417-25. 2005
    ..However, patients with stage I disease of other germ cell histologies, as well as advanced-stage disease of all germ cell histologies, require adjuvant treatment with bleomycin, etoposide and cisplatin...
  14. doi request reprint Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation
    Weiwei Feng
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 112:1489-502. 2008
    ..Two imprinted genes, paternally expressed 3 (PEG3) and aplasia Ras homologue member I (ARHI), are the most frequently down-regulated in ovarian cancers on gene expression arrays...
  15. ncbi request reprint Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma
    Russell R Broaddus
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:87-94. 2006
    ..It was the purpose of this study to pathologically characterize a series of HNPCC associated endometrial carcinomas...
  16. pmc Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression
    Shannon N Westin
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 8:2126-35. 2009
    ..This proof-of-concept study demonstrates that biomarker analysis may play a role in clinical decision making for the therapy of women with endometrial cancer...
  17. ncbi request reprint Expression of imatinib mesylate-targeted kinases in endometrial carcinoma
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Gynecol Oncol 95:32-6. 2004
    ..To determine whether imatinib mesylate could be a potentially useful agent in the treatment of endometrial cancer, we assessed the expressions of Abl, c-Kit, and PDGFR in both primary and recurrent endometrial carcinoma...
  18. pmc CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity
    Qian Zhang
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 133:83-9. 2014
    ..We identified CGRRF1 (cell growth regulator with ring finger domain 1) as a novel metformin-responsive gene and characterized its possible role in endometrial cancer prevention...
  19. ncbi request reprint Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome
    Kathleen M Schmeler
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    N Engl J Med 354:261-9. 2006
    ..We designed this study to determine the reduction in the risk of gynecologic cancers associated with prophylactic hysterectomy and bilateral salpingo-oophorectomy in women with the Lynch syndrome...
  20. ncbi request reprint Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon
    Rebecca T Marquez
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:6116-26. 2005
    ..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble...
  21. ncbi request reprint Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations
    Kathleen M Schmeler
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
    Obstet Gynecol 108:515-20. 2006
    ..The objective of this study was to evaluate clinical factors associated with choosing prophylactic bilateral salpingo-oophorectomy (BSO) over surveillance in women with a BRCA1 or BRCA2 mutation...
  22. ncbi request reprint Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
    David M Gershenson
    Department of Gynecologic Oncology and Pathology, The University of Texas M D Anderson Cancer Center, Houston, 77230 1439, USA
    Obstet Gynecol 108:361-8. 2006
    ..To analyze the clinical behavior of patients with stage II-IV low-grade serous carcinoma of the ovary seen at our institution who underwent primary surgery followed by platinum-based chemotherapy...
  23. doi request reprint Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma
    Shannon N Westin
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:2659-67. 2011
    ..Little is known regarding patient satisfaction levels with risk-reduction strategies. Thus, the authors sought to determine levels of patient satisfaction with PS versus RRSO and to identify factors that may influence satisfaction...
  24. pmc Chemopreventive effects of metformin on obesity-associated endometrial proliferation
    Qian Zhang
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Am J Obstet Gynecol 209:24.e1-24.e12. 2013
    ..In this study, we investigate whether pharmacologic agents that modulate insulin sensitivity or normalize insulin levels will diminish the proliferative response to estrogen...
  25. ncbi request reprint Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis
    Kwong Kwok Wong
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Pathol 26:404-9. 2007
    ..These differences may lead to the development of different therapeutic strategies for women with either the low-grade or the high-grade form of OSC...
  26. ncbi request reprint Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome?
    Pamela T Soliman
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 23:9344-50. 2005
    ..The purpose of our study was to determine the likelihood of MMR defects (MSH2, MSH6, MLH1) in women with synchronous endometrial and ovarian cancer...
  27. pmc BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas
    Kwong Kwok Wong
    Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Pathol 177:1611-7. 2010
    ..In addition, advanced-stage, low-grade carcinoma patients with BRAF or KRAS mutation have a better apparent clinical outcome. However, further investigation is needed...
  28. ncbi request reprint Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma
    Hyun S Shvartsman
    Department of Gynecologic Oncology, Unit 1362, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 105:625-9. 2007
    ..The purpose of this study was to compare the outcomes of patients with these two tumor types...
  29. doi request reprint Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma
    Karen H Lu
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Smithville, Texas 78957, USA
    Clin Cancer Res 14:2543-50. 2008
    ....
  30. ncbi request reprint Potential markers that complement expression of CA125 in epithelial ovarian cancer
    Daniel G Rosen
    Department of Pathology, University of Texas M D Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 99:267-77. 2005
    ..Serum tumor markers that can be detected in ovarian cancers that lack CA125 expression might improve the sensitivity for early detection...
  31. ncbi request reprint Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas
    Jimmy J Caudell
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Appl Immunohistochem Mol Morphol 13:167-70. 2005
    ..These results indicate that many uterine sarcomas express 1 or more of the kinases targeted by imatinib mesylate and that further investigation of imatinib as a therapy for uterine sarcomas is warranted...
  32. pmc Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis
    Melinda S Yates
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Prev Res (Phila) 4:463-70. 2011
    ..We present an updated model for BRCA1/2 mutation-associated ovarian and fallopian tube carcinogenesis, which may aid in identifying improved prevention strategies for high-risk women who delay or decline RRSO...
  33. ncbi request reprint Her-2/neu overexpression and amplification in uterine papillary serous carcinoma
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 440, Houston, TX 77030 4009, USA
    J Clin Oncol 22:3126-32. 2004
    ..The purpose of this study was to evaluate the protein expression and gene amplification of Her-2/neu in UPSC and to determine its prognostic value...
  34. doi request reprint Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities
    Larissa A Meyer
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Obstet Gynecol 115:945-52. 2010
    ..To estimate the incidence of genetic counseling referral for ovarian cancer patients who are at substantial risk for a BRCA1 or BRCA2 mutation...
  35. ncbi request reprint Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases
    Pamela T Soliman
    Department of Gynecologic Oncology, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Gynecol Oncol 94:456-62. 2004
    ..The purpose of this study was to characterize patients diagnosed with synchronous primary cancers of the endometrium and ovary with an emphasis on risk factors...
  36. ncbi request reprint The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary
    Rosemarie E Schmandt
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer Biol Ther 5:1136-41. 2006
    ..Its expression in normal ovary and ovarian tumors has not previously been described, and is the focus of this study...
  37. pmc The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer
    Erin R King
    Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg Pathol 35:904-12. 2011
    ..The progression of SBOT to LG serous ovarian carcinoma may involve the dedifferentiation of ciliated cells. AGR3 could serve as a prognostic marker for survival in patients with LG and HG serous ovarian carcinomas...
  38. ncbi request reprint Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk
    Jonathan C Oh
    The Department of Gynecological Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Epidemiol Biomarkers Prev 13:748-52. 2004
    ..Further validation of these results is needed to determine the potential usefulness of risk assessment...
  39. ncbi request reprint Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival
    Daniel G Rosen
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6559-66. 2004
    ..To determine the relevance of these observations to clinical cancer, we have now measured ARHI expression in normal, benign and malignant ovarian tissues using immunohistochemistry and in situ hybridization...
  40. doi request reprint A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium
    Anuja Jhingran
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 129:304-9. 2013
    ....
  41. pmc PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas
    Celestine S Tung
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mod Pathol 22:1243-50. 2009
    ....
  42. ncbi request reprint Association between adiponectin, insulin resistance, and endometrial cancer
    Pamela T Soliman
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 106:2376-81. 2006
    ..The purpose of the current study was to determine whether there was an independent association between adiponectin level and endometrial cancer...
  43. doi request reprint Primary peritoneal cancer after bilateral salpingo-oophorectomy in two patients with Lynch syndrome
    Kathleen M Schmeler
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Obstet Gynecol 115:432-4. 2010
    ..We describe two cases of primary peritoneal cancer after BSO in women with Lynch syndrome or HNPCC...
  44. doi request reprint Prospective evaluation of insulin resistance among endometrial cancer patients
    Jennifer K Burzawa
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 70030 4009, USA
    Am J Obstet Gynecol 204:355.e1-7. 2011
    ..Whereas diabetes also increases the risk, little is known about related insulin resistance (IR). The purpose of this study was to determine the prevalence of IR in newly diagnosed EC patients...
  45. pmc Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1598-604. 2009
    ..Women at a high risk for breast cancer are offered choices for screening or prophylactic surgeries. The aim of this study was to evaluate opinions regarding screening and surgical strategies in high-risk women...
  46. pmc Enhanced estrogen-induced proliferation in obese rat endometrium
    Qian Zhang
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Obstet Gynecol 200:186.e1-8. 2009
    ..We tested the hypothesis that the proliferative estrogen effect on the endometrium is enhanced in obese vs lean animals...
  47. doi request reprint Limited public knowledge of obesity and endometrial cancer risk: what women know
    Pamela T Soliman
    Department of Gynecologic Oncology, and Division of Quantitative Sciences, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Obstet Gynecol 112:835-42. 2008
    ..To estimate if women in the general population are aware of the relationship between obesity and cancer risk, and to identify groups who may benefit from educational programs...
  48. pmc Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes
    Li E Wang
    Department of Epidemiology, Unit 1365, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Cancer Res Clin Oncol 138:377-85. 2012
    ..In this candidate pathway analysis, we investigated associations between genetic variations in these two pathways and both risk and clinical outcomes of endometrial cancer...
  49. pmc Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome
    Shannon N Westin
    Department of Gynecologic Oncology and Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:5965-71. 2008
    ..We performed a case-comparison study to document the clinicopathologic characteristics of LUS tumors and their association with risk factors for endometrial cancer...
  50. ncbi request reprint STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study
    Michael R Milam
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, 1155 Herman P Pressler St, CPB 6 3244, Unit 1362, Houston, TX 77030, USA
    Gynecol Oncol 107:71-4. 2007
    ..We hypothesized that STK15 polymorphisms might modulate the risk of uterine cancer...
  51. doi request reprint Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
    David M Gershenson
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 114:48-52. 2009
    ..The purpose of this study was to further characterize this chemoresistance in recurrent low-grade serous ovarian carcinoma...
  52. ncbi request reprint Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis
    Karen H Lu
    Ovarian Cancer Research Laboratory, Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3291-300. 2004
    ..Consequently, use of multiple markers in combination might detect a larger fraction of early-stage ovarian cancers...
  53. ncbi request reprint Endometrial cancer in young, normal-weight women
    Kathleen M Schmeler
    Department of Gynecologic Oncology, The University of Texas, M D Anderson Cancer Center, PO Box 301439, Unit 1362, Houston, TX 77230 1439, USA
    Gynecol Oncol 99:388-92. 2005
    ..To determine if young, normal-weight women with endometrial cancer have unique risk factors and clinical characteristics when compared with young, overweight and obese women with endometrial cancer...
  54. ncbi request reprint Risk factors for young premenopausal women with endometrial cancer
    Pamela T Soliman
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Obstet Gynecol 105:575-80. 2005
    ..The objective of this study was to conduct a clinical and pathologic review of endometrial cancers diagnosed in premenopausal women aged younger than 50 years, to better identify the risk factors for this subgroup of women...
  55. pmc Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers
    Laura L Holman
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Electronic address
    Gynecol Oncol 133:283-6. 2014
    ..We aimed to determine the interest in a study of PSDO among these women...
  56. pmc What women with ovarian cancer think and know about genetic testing
    Robin A Lacour
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 3721, USA
    Gynecol Oncol 111:132-6. 2008
    ..With the prospect of BRCA-directed therapeutics, we investigated ovarian cancer patients' knowledge and willingness to undergo genetic testing...
  57. doi request reprint A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 116:5415-9. 2010
    ..Loss of PTEN or activation of PIK3CA results in constitutive activation of AKT, which leads to up-regulation of mammalian target of rapamycin (mTOR). Everolimus is an oral rapamycin analog that acts by selectively inhibiting mTOR...
  58. pmc Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
    Bryan T J Hennessy
    Department of Gynecology Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:3570-6. 2010
    ..3%. It is important to determine the frequency of somatic BRCA(1/2) changes, given the sensitivity of BRCA-mutated cancers to poly (ADP ribose) polymerase-1 (PARP1) inhibitors and platinum analogs...
  59. doi request reprint Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
    Marisa A Vineyard
    University of Texas Health Science Center, Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA
    Gynecol Oncol 120:229-32. 2011
    ....
  60. ncbi request reprint Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Obstet Gynecol 104:255-60. 2004
    ..The purpose of this study was to estimate whether a history of tamoxifen use is a prognostic factor for such patients...
  61. pmc Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening
    Laura L Holman
    Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Am J Obstet Gynecol 210:257.e1-6. 2014
    ..We evaluated baseline knowledge of ovarian cancer risk and perceptions toward ovarian cancer screening (OCS) by initiating the normal risk ovarian screening study...
  62. ncbi request reprint Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 91:463-9. 2003
    ..The identified characteristics were then correlated with overall survival (OS)...
  63. pmc Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry
    Mala Pande
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Unit 1365, PO Box 301439, Houston, TX, 77230 1439, USA
    Fam Cancer 11:441-7. 2012
    ..This has clinical relevance both for diagnosis of Lynch syndrome and surveillance for cancers of different sites during follow-up of these patients...
  64. doi request reprint Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study
    Diane C Bodurka
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:3087-94. 2012
    ....
  65. pmc Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome
    Larissa I Batista
    Department of Surgical Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 8:101. 2008
    ..We aimed to assess the feasibility of coordinated PM and BSO in hereditary breast-ovarian cancer syndrome...
  66. doi request reprint Obstetrics/gynecology residents' knowledge of hereditary breast and ovarian cancer and Lynch syndrome
    Kaylene J Ready
    Department of Breast Medical Oncology Unit 1354, The University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Cancer Educ 25:401-4. 2010
    ..Cancer genetics education programs should place more emphasis on the areas in which residents' appeared to be deficient in order to aid future physicians in the identification of high-risk individuals...
  67. pmc Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer
    Astrid M Eder
    Department of Molecular Therapeutics, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:12519-24. 2005
    ..These results implicate PKCiota as a potential oncogene in ovarian cancer regulating epithelial cell polarity and proliferation and suggest that PKCiota is a novel target for therapy...
  68. pmc Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study
    Pamela T Soliman
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Am J Obstet Gynecol 204:167.e1-5. 2011
    ..Adiponectin, a protein secreted by adipose cells, is inversely associated with endometrial cancer. Our objective was to assess prediagnostic adiponectin levels in relation to risk of endometrial cancer...
  69. ncbi request reprint Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome
    Ann H Klopp
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:226-36. 2008
    ..In addition we aimed to identify a gene expression profile that was associated with clinical outcome...
  70. ncbi request reprint Supracervical hysterectomy in patients with advanced epithelial ovarian cancer
    Michael R Milam
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Obstet Gynecol 109:641-6. 2007
    ..To assess whether supracervical hysterectomy (SCH) is a reasonable alternative to total abdominal hysterectomy in patients with advanced ovarian cancer...
  71. ncbi request reprint Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas
    Weiguo Wu
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 63:6195-9. 2003
    ..However, in UPSC/CCC, cdc25B is highly expressed without coordinate increase in phosphorylated ER-alpha. Cdc25B may play important roles in the development and progression of EEC and UPSC/CCC by different mechanisms...
  72. ncbi request reprint Are women ready for the HPV vaccine?
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 103:151-4. 2006
    ..Because vaccination for both boys and girls will be critical to reduce the incidence of this disease, we evaluated the willingness of women to accept the HPV vaccine and to consent to having their children vaccinated...
  73. ncbi request reprint Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome
    Russell R Broaddus
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mod Pathol 17:981-9. 2004
    ..Therefore, when analyzing unusual tumors in patients with known or suspected HNPCC syndrome, we advocate the performance of immunohistochemistry for mismatch repair gene products in addition to microsatellite instability analysis...
  74. doi request reprint Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer
    Molly S Daniels
    Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    Genet Med 11:624-8. 2009
    ..To determine when, in reference to the course of their treatment, women with ovarian cancer are seen for genetic counseling, as well as to determine what factors influence this timing...
  75. pmc Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
    Donna Badgwell
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, and Program in Women s Oncology, Women s and Infants Hospital, Providence, RI 02905, USA
    Gynecol Oncol 106:490-7. 2007
    ..Mesothelin has been detected in serum from patients with ovarian cancer, but has not been previously reported in urine...
  76. ncbi request reprint Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
    Michael R Milam
    Department of Gynecologic Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Obstet Gynecol 196:247.e1-5. 2007
    ..The objective of this study was to evaluate an oral mTOR inhibitor (mTOR-I) on the reduction of endometrial hyperplasia in an animal model...
  77. doi request reprint Accuracy of the BRCAPRO model among women with bilateral breast cancer
    Kaylene J Ready
    University of Texas M D Anderson Cancer Center, Department of Breast Medical Oncology, Unit 1354, P O Box 301439, Houston, TX 77230 1439, USA
    Cancer 115:725-30. 2009
    ..The objectives of this study were to determine the accuracy of the BRCAPRO model among women with bilateral breast cancer and to determine whether their mutation status was dependent on their age at first diagnosis...
  78. ncbi request reprint The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
    Kwai Wa Cheng
    Department of Molecular Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA
    Nat Med 10:1251-6. 2004
    ..Overall, these studies implicate RAB25, and thus the RAB family of small G proteins, in aggressiveness of epithelial cancers...
  79. doi request reprint A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges
    Molly S Daniels
    U T M D Anderson Cancer Center, Department of Gynecologic Oncology, Unit 1362, PO Box 301439, Houston, TX 77230 1439, USA
    Fam Cancer 10:193-7. 2011
    ..Further attention and research should be directed towards provision of genetic counseling and testing during end of life care...
  80. ncbi request reprint Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases
    Michael T Deavers
    Department of Pathology and Gynecologic Oncology, University of Texas, Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Surg Pathol 26:1129-41. 2002
    ..Additionally, our long-term follow-up of patients with typical SLMP indicates that a number of these tumors do not follow a benign course and supports their continued designation as borderline neoplasms...
  81. ncbi request reprint Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium
    Rosemarie E Schmandt
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:758-64. 2003
    ..Immunohistochemical expression of c-ABL, PDGFR-beta, and c-KIT was evaluated in ovarian carcinomas to determine whether treatment with imatinib mesylate might be feasible...
  82. ncbi request reprint Overexpression of kallikrein 10 in epithelial ovarian carcinomas
    Hyun S Shvartsman
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 90:44-50. 2003
    ..We investigated whether KLK10 and its related protein, hK10, might serve as equally accurate markers for ovarian carcinoma...
  83. pmc Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer
    Charlotte H Clarke
    U T M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 122:548-53. 2011
    ..We have attempted to improve sensitivity by combining CA125 with proteomic markers...
  84. doi request reprint Genetic polymorphisms and endometrial cancer risk
    Larissa A Meyer
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, 1155 Herman P Pressler St, CPB 6 3244, Unit 1362, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 8:1159-67. 2008
    ..In addition, the challenges of genetic association studies, such as power and bias, and the need for validation of promising findings are explored...
  85. doi request reprint Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome
    Janice S Kwon
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 113:326-35. 2008
    ..Screening and prophylactic surgery have been recommended as prevention strategies. In this study, the authors estimated the net health benefits and cost-effectiveness of these strategies in a Markov decision-analytic model...
  86. doi request reprint Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes
    Amanda C Brandt
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Unit 1362, P O Box 301439, Houston, TX 77230 1439, USA
    Fam Cancer 9:479-87. 2010
    ..Since 68% of physicians had incorrect or limited knowledge of PGD for hereditary cancer, there is a need for additional education...
  87. ncbi request reprint Women with HNPCC: a target population for the chemoprevention of gynecologic cancers
    Russell R Broaddus
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Front Biosci 11:2077-80. 2006
    ..The purpose of this review is to provide an analytical background about the current knowledge regarding gynecological cancers in patients with HNPCC...
  88. doi request reprint Endometrial cancer in an adolescent: a possible manifestation of Cowden syndrome
    Kathleen M Schmeler
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Obstet Gynecol 114:477-9. 2009
    ..Cowden syndrome is an autosomal dominant disorder characterized by the development of multiple intestinal hamartomas, distinctive mucocutaneous lesions, and an increased risk of endometrial, breast, and thyroid cancer...
  89. ncbi request reprint Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer
    Zhensheng Liu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:4968-76. 2005
    ..The purpose of this research was to compare methylation status and mRNA expression of p15INK4b and p16INK4a in serous epithelial ovarian cancer tissues and normal ovarian tissues...
  90. doi request reprint Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women
    Janice S Kwon
    Department of Gynecologic Oncology, MD Anderson Cancer Center, Houston, TX, USA
    Obstet Gynecol 112:56-63. 2008
    ..We estimated the net health benefits and cost-effectiveness of these strategies in a hypothetical cohort of obese women...
  91. ncbi request reprint Practice patterns of SGO members for stage IIIA endometrial cancer
    Christine M Lee
    Department of Gynecologic Oncology, Division of Surgery, Unit 440, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Gynecol Oncol 98:77-83. 2005
    ..The aim of this study was to survey the Society of Gynecologic Oncologists (SGO) members and fellows about their approach to the treatment of patients with stage IIIA endometrial cancer...
  92. pmc Endometrial cancer and Lynch syndrome: clinical and pathologic considerations
    Larissa A Meyer
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Control 16:14-22. 2009
    ..Lynch syndrome is associated with early onset of cancer and the development of multiple cancer types, particularly colon and endometrial cancer...
  93. ncbi request reprint Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients
    J Salvador Saldivar
    Department of Gynecology Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Gynecol Oncol 107:S223-9. 2007
    ..We hypothesized that genetic polymorphisms in XP genes may predict clinical response to platinum chemotherapeutic treatment and survival in women with gynecological cancers...
  94. pmc MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma
    Ajoy K Samanta
    Department of Biochemistry and Molecular Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:3897-908. 2009
    ..The authors have demonstrated that MEKK3 plays a critical role in cytokine-mediated NFkappaB activation, and that stable expression of MEKK3 in cultured cells leads to increased NFkappaB activity...
  95. ncbi request reprint beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma
    Christine M Lee
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, TX 77030, Houston, USA
    Gynecol Oncol 88:363-8. 2003
    ..beta-Catenin has been previously associated with oncogenic activity in human cancers. We evaluated whether beta-catenin also plays a role in papillary serous ovarian neoplasms...
  96. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....
  97. ncbi request reprint Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer
    Jae Hoon Kim
    Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:4782-91. 2003
    ..090 in 26 normal women. This investigation has shown that the Ep-CAM autoantibody was found to be associated with ovarian cancer and suggested that future research assessing its clinical usefulness would be worthwhile...
  98. ncbi request reprint BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model
    Kristen J Vogel
    Center for Medical Genetics, Evanston Northwestern Healthcare, Evanston, IL, USA
    J Clin Oncol 25:4635-41. 2007
    ..This retrospective study reports the mutation frequency and spectrum of BRCA1 and BRCA2 mutations in a Hispanic population and evaluates the BRCAPRO model in Hispanics...
  99. ncbi request reprint Cyclin E deregulation alters the biologic properties of ovarian cancer cells
    Isabelle Bedrosian
    Department of Surgical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Oncogene 23:2648-57. 2004
    ..Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors...
  100. ncbi request reprint Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions
    Johnathan M Lancaster
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Gynecol Oncol 107:159-62. 2007
    ..This commentary provides guidance on identification of patients who may benefit from hereditary cancer risk assessment for Hereditary Breast/Ovarian Cancer and the Lynch/Hereditary Non-Polyposis Colorectal Cancer syndrome...
  101. ncbi request reprint Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary
    Tomas Bonome
    Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 65:10602-12. 2005
    ..Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype...

Research Grants3

  1. Annual Uterine Cancer Symposium
    Karen Lu; Fiscal Year: 2007
    ..For each symposium, a mixture of clinical topics and basic science topics will be presented to promote the development of quality translational research. ..
  2. MD Anderson Cancer Ctr. Gynecology SPORE: Uterine Cancer
    Karen Lu; Fiscal Year: 2007
    ..D., Principal Investigator) will encourage faculty development research. An Internal Advisory Committee and External Advisory Committee will assist in scientific and clinical planning and evaluation of projects. ..